The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Nov. 20, 2018
Applicant:

Basilea Pharmaceutica International Ag, Basel, CH;

Inventors:

Felix Bachmann, Basel, CH;

Heidi Lane, Basel, CH;

Paul McSheehy, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4245 (2006.01); A61P 35/04 (2006.01); A61K 9/00 (2006.01); A61K 31/357 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4245 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/357 (2013.01); A61P 35/04 (2018.01);
Abstract

The present invention provides pharmaceutical combinations comprising (a) a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, hydroxyl, amino, lower alkylamino, lower dialkylamino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; R1 represents hydrogen or cyano-lower alkyl; and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (II) (eribulin) or a pharmaceutically acceptable salt thereof and the use of the pharmaceutical combinations in the treatment of neoplastic diseases.


Find Patent Forward Citations

Loading…